Weight Loss from Type 2 Diabetes Combination Drug Treatment
Discover now what two drugs taken together successfully treats Type 2 diabetes, and also causes weight loss.
Type 2 Diabetes Solutions Sought
A recent news article from Thomas Jefferson University reports that a new study published in the journal Diabetes Care by university researchers, demonstrates a longer-lasting treatment for Type 2 diabetes patients. This treatment is a special two-drug combination that remains effective longer toward controlling blood sugar levels than other diabetes medications taken singularly, and… also leads to weight loss.
One of the difficulties of medications for treating Type 2 diabetes is that while many work for the short term, some—like the commonly prescribed drug Metformin—over time lose their efficacy in some patients, thereby requiring new treatment approaches.
According to the news release:
“Many therapies in diabetes management are short-lived, which is why it’s useful to test for long-term effect,” says Serge Jabbour, MD, director of the division of endocrinology and the Diabetes Center at Thomas Jefferson University and lead author of the study. “Our study showed that a combo regimen of dapagliflozin and exenatide continued to control patients’ glucose for over two years. This is a very encouraging.”
The Diabetes Trial Study
In a double-blind, phase 3, randomized controlled trial, the research team enrolled 695 adults whose Type 2 diabetes was not controlled with metformin. The Type 2 diabetes drugs tested on the adults included:
• Metformin—a class of drugs called biguanides that helps control the amount of glucose in your blood by decreasing the amount of glucose you absorb from your food and the amount of glucose made by your liver.
• Dapagliflozin—a class of drugs called “sodium–glucose cotransporter-2” (SGLT2) inhibitors that cause excess glucose to be excreted in the urine.
• Exenatide—a class of drugs called “glucagon-like peptide-1 receptor agonists” (GLP-1RAs), which enhance glucose-dependent insulin secretion, lower hepatic glucose output, slow gastric emptying, and increases satiety (feelings of fullness).
The study participants were divided into three groups: One that received weekly exenatide injections in addition to metformin; one that took daily dapagliflozin pills in addition to metformin; and, one that received both exenatide and dapagliflozin.
What the results showed was that the group of patients who received both exenatide and dapagliflozin had better glycemic control than the other two groups in the study participants. The exenatide and dapagliflozin combo groups glucose control proved to remain stable for the duration of the extended two-year study period. Furthermore, the study also showed “…a clinically relevant reduction in weight and blood pressure, measures that can contribute to Type-2 diabetes and overall health.”
“These two classes work synergistically to help control a Type-2 diabetes patient’s glucose levels, and other measures associated with diabetes,” says Dr. Jabbour. “We can now feel more confident about prescribing these medications long term.”
For more about controlling your Type 2 diabetes and losing weight, here is an informative article about a non-medication option: “Study shows two weight loss methods diabetics are cured with, work equally well.”
Timothy Boyer has a Ph.D. in Molecular and Cellular Biology from the University of Arizona. For 20+ years he has been employed as a freelance health and science writer. Today, with an eye on the latest news, Timothy continues writing about science with a focus on what you need to know for healthier living. For continual updates about health, you can also follow Timothy on Twitter at TimBoyerWrites.
Image Source: Courtesy of Arek Socha from Pixabay.
“Combo-Drug Treatment for Type 2 Diabetes Remains Effective After Two Years” Thomas Jefferson University news 2 Nov. 2020.
"Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial" Serge A. Jabbour, Juan P. Frias, Azazuddin Ahmed, Elise Hardy, Jasmine Choi, C. David Sjostrom, and Cristian Guja; Diabetes Care, Aug. 2020, dc191350.